A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations
A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancie
A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma
Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
